Who is sponsoring NCT00002455?

NCT00002455 is sponsored by Centro Oncologico de Excelencia.

What condition does NCT00002455 study?

NCT00002455 studies Breast Cancer, Colorectal Cancer, Melanoma (Skin).

What drugs are being tested in NCT00002455?

Interventions: Corynebacterium granulosum P40, adjuvant therapy.

What is the status of NCT00002455?

NCT00002455 is currently UNKNOWN.

Last reviewed 2013-08-06 · How we verify

Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts

NCT00002455 Phase 3 UNKNOWN

RATIONALE: Immunotherapy uses different ways to stimulate the immune system and stop cancer cells from growing. Immunotherapy biological extracts may be useful as adjuvant therapy in treating patients who have had surgery for breast cancer, colon cancer, or melanoma. PURPOSE: Phase III trial to study the effectiveness of Corynebacterium granulosum extract as maintenance immunotherapy following surgery in treating patients with breast cancer, colon cancer, or melanoma.

Details

Lead sponsor	Centro Oncologico de Excelencia
Phase	Phase 3
Status	UNKNOWN
Start date	1971-04

Conditions

Breast Cancer
Colorectal Cancer
Melanoma (Skin)

Interventions

Corynebacterium granulosum P40
adjuvant therapy

Primary outcomes

Recurrence
Response to study parameters
Survival rate

Countries

Argentina